Reduction of aspirin-induced gastroduodenal mucosal damage with ranitidine.
A randomized, double-blind, placebo-controlled study was conducted to determine if concomitant administration of ranitidine, an H2-receptor antagonist, could reduce the gastroduodenal mucosal damage associated with short-term (3 day) aspirin therapy. Nineteen subjects received ranitidine 150 mg b.i.d. plus aspirin 650 mg q.i.d., and 21 received placebo b.i.d. plus aspirin 650 mg q.i.d. for 3 days. Gastric injury and duodenal injury were assessed separately on the basis of pre- and posttreatment endoscopic examinations. The ranitidine/aspirin group had significantly less mucosal damage in the stomach (p less than or equal to 0.01) and duodenum (p less than 0.05) than the placebo/aspirin group. There was no significant difference in mean serum salicylate levels between treatment groups after 3 days of aspirin consumption, indicating that the protective effect was achieved without compromising salicylate absorption.
D000293:Adolescent; D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000633:toxicity*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005753:Gastric Mucosa / Q000187:drug effects*; D005773:Gastroscopy; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects*; D008297:Male; D011897:Random Allocation; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D011899:Ranitidine; D001241:Aspirin